Looking ahead, revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%.

Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) (“BAM”), a leading global alternative asset manager headquartered in New York with over $1 trillion of assets under management, today announced ...